Myelosuppression Clinical Trials in Xiamen, Fujian
2 recruitingXiamen, Fujian, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
NSCLC (Advanced Non-small Cell Lung Cancer)EGFRMyelosuppression
The First Affiliated Hospital of Xiamen University49 enrolled1 locationNCT06992739
Recruiting
Phase 2
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
Non-small Cell Lung CancerMyelosuppression
The First Affiliated Hospital of Xiamen University33 enrolled1 locationNCT06929936